Jaguar health to spotlight company's commercial focus on cancer supportive care at american society for radiation oncology (astro) annual meeting for fda-approved gelclair oral mucositis product in advance of october 2024 gelclair launch

Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a national comprehensive cancer network task force up to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy san francisco, ca / accesswire / september 24, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that jaguar family company napo pharmaceuticals (napo) is exhibiting gelclair ® , the fda-approved oral mucositis prescription product, at the american society for radiation oncology (astro) annual meeting , which takes place september 29 - october 2, 2024 in washington, dc. jaguar plans to begin the u.s. commercial launch in october 2024 for gelclair.
JAGX Ratings Summary
JAGX Quant Ranking